RecruitingNot ApplicableNCT07231471

Platelet Rich Plasma for Musculoskeletal Conditions

Sponsor

University of Utah

Enrollment

10,000 participants

Start Date

Dec 29, 2025

Study Type

INTERVENTIONAL

Conditions

Osteoarthritis (OA) of the hip Osteoarthritis (OA)Osteoarthritis Ankle Plantar Fasciitis of Both Feet Epicondylitis of the Elbow Osteoarthritis (OA) of the Shoulder Elbow Osteoarthritis Osteoarthritis(OA) of the knee Tendinopathy

Summary

The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction. This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Platelet Rich Plasma Injection and a medical device called Platelet Rich Plasma Preparation for people with elbow osteoarthritis, epicondylitis of the elbow, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPlatelet Rich Plasma Injection

Participants who are eligible and provide consent to participate will undergo a Platelet-Rich Plasma (PRP) injection. Their blood will be analyzed using a cell counter, and they will be asked to complete follow-up surveys at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.

DEVICEPlatelet Rich Plasma Preparation

The patient's blood is collected into syringes. That blood is spun in a centrifuge at high speeds, which separates their blood into layers (red blood cells, white blood cells, and plasma). The plasma portion, which contains the platelets, is transferred to a different syringe for later injection. In some cases, the plasma is spun in the centrifuge again (a "double spin" technique) to further concentrate the platelets in the plasma. The patient's blood is not exposed to air, and it is transferred by tubing between syringes with a Luer Lock connection.